Virscio is a translational research and development company devoted to providing predictive preclinical research models and services to accelerate therapeutic candidate evaluation and reduce the risk of clinical failure. Virscio engages with leading pharmaceutical, biotechnology and academic sponsors and collaborators to design and execute a wide range of preclinical safety studies, from pilot de-risking studies through IND-enabling GLP studies.